WEATHER ALERT: January 25, 2026 (5:15 PM): We are actively monitoring the weather in our area to ensure patient and staff safety. Our offices will be CLOSED on Monday (January 26) with an ON-TIME OPENING on Tuesday (January 27). Patients in active cancer treatment will continue to be prioritized to ensure continuity of care. If you are undergoing active cancer treatment, a team member will reach out to advise of any changes to your appointment. Please continue to check our website for the latest weather updates. Thank you for your patience and understanding.
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to an as of yet undisclosed cytotoxic drug, with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin ADC BMS-986148 targets and binds to the tumor-associated antigen mesothelin. Upon internalization, the cytotoxic agent kills or prevents cellular proliferation of mesothelin-expressing tumor cells through an as of yet undescribed mechanism of action. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
